| Bio-medical |
 |
| |
|
|
|
|
|
|
|
|
| Haemoscope TEG SYSTEM |
The TEG system is comprised of the TEG analyzer and the TEG analytical software, which together provide a complete picture of the formation and dissolution of the clot, showing the balance or imbalance of the two systems.
Haemoscope's TEG analyzer is the only hemostasis analyzer available on the market that follows the reliable and proven model developed by Prof. Helmut Hartert in Germany in the 1940's. Haemoscope has continually improved the reliability and ergonomics of the original, until today, over 25 years later, we provide the gold standard in hemostasis testing. In use at the most prestigious teaching hospitals around the world, attested to by the most prominent clinicians, and relied upon in the most advanced clinical procedures, the TEG system has proven itself time and time again.
| |
|
| |
|
|
|
| |
|
The ThrombelastographR (TEG ) Coagulation Analyzer 5000 series is a non-invasive diagnostic instrument designed to monitor and analyze the coagulation state of a blood sample in order to assist in the assessment of patient clinical haemostasis conditions. The TEG analyzer is indicated for use with patients where an evaluation of their blood coagulation properties is desired. Coagulation evaluations are commonly used to assess clinical conditions such as post-operative hemorrhage and/or thrombosis during and following cardiovascular surgery, organ transplantation, trauma, and cardiology procedures.
TEG® analyzer technology
The TEGR analyzer has a sample cup that oscillates back and forth constantly at a set speed through an arc of 4°45'. Each rotation lasts ten seconds. A whole blood sample of 360 ul is placed into the cup, and a stationary pin attached to a torsion wire is immersed into the blood. When the first fibrin forms, it begins to bind the cup and pin, causing the pin to oscillate in phase with the clot. The acceleration of the movement of the pin is a function of the kinetics of clot development.
The torque of the rotating cup is transmitted to the immersed pin only after fibrin-platelet bonding has linked the cup and pin together. The strength of these fibrin-platelet bonds affects the magnitude of the pin motion, such that strong clots move the pin directly in phase with the cup motion. Thus, the magnitude of the output is directly related to the strength of the formed clot.
As the clot retracts or lyses, these bonds are broken and the transfer of cup motion is diminished.
The rotation movement of the pin is converted by a mechanical-electrical transducer to an electrical signal which can be monitored by a computer.
The resulting hemostasis profile is a measure of the time it takes for the first fibrin strand to be formed, the kinetics of clot formation, the strength of the clot (in shear elasticity units of dyn/cm2) and dissolution of clot.
|
|
|
|
|
| |
|
|
|
|
|
In 1987, Drs. DeBakey and Noon designed a low-cost, low-power, implantable ventricular assist device (VAD). NASA began formal funding of the development of the device in 1991. In 1996, MicroMed Cardiovascular, Inc. received an exclusive license from NASA to use this rotary blood pump for cardiovascular applications. MicroMed then began the development of the critical support systems that would allow the device (system) to be approved by regulatory agencies and to be utilized in lifesaving applications on near 175,000 patients in USA.
|
|
|
|
|
| |
| |
|
|
|
|
|
| |
